Ups and downs--and ups in the antiviral therapy of HIV infection.
作者信息
Weller I V, Williams I
机构信息
Department of Sexually Transmitted Diseases, University College London Medical School.
出版信息
Genitourin Med. 1996 Feb;72(1):2-5. doi: 10.1136/sti.72.1.2.
Abstract
摘要
相似文献
1
Ups and downs--and ups in the antiviral therapy of HIV infection.HIV感染抗病毒治疗的起伏——以及进展
Genitourin Med. 1996 Feb;72(1):2-5. doi: 10.1136/sti.72.1.2.
2
Current management of HIV infection in children.
Pediatr Ann. 1993 Jul;22(7):428-35. doi: 10.3928/0090-4481-19930701-09.
3
Nucleoside therapy for HIV infection--some answers, many questions.用于治疗HIV感染的核苷疗法——一些答案，诸多问题。
N Engl J Med. 1992 Aug 27;327(9):639-41. doi: 10.1056/NEJM199208273270912.
4
Managing HIV disease after Delta.德尔塔变异株出现后的艾滋病管理
BMJ. 1996 Mar 2;312(7030):521-2. doi: 10.1136/bmj.312.7030.521.
5
[Anti-HIV therapy (1987-1994): from nothing to confusion].[抗逆转录病毒疗法（1987 - 1994年）：从无到乱]
Med Clin (Barc). 1995 Apr 1;104(12):463-7.
6
7
Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1.对于感染HIV-1的免疫功能低下的成年人，联合用药可能比单独使用齐多夫定效果更好。
Commun Dis Rep CDR Wkly. 1995 Oct 20;5(42):209.
8
9
[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].[抗病毒化疗的当前进展。第4部分：膦甲酸钠、齐多夫定、去羟肌苷]
Fortschr Med. 1994 May 10;112(13):190-1.
10
Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease.抗艾滋病毒疗法降低中期艾滋病毒疾病患者患艾滋病和死亡的风险。
AIDS Patient Care. 1995 Dec;9(6):303.
引用本文的文献
1
The Medication Attribution Scale: perceived effects of antiretrovirals and quality of life.药物归因量表：抗逆转录病毒药物的感知效果与生活质量
Qual Life Res. 1998 Apr;7(3):205-14. doi: 10.1023/a:1024913425993.
本文引用的文献
1
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.齐多夫定用于无症状HIV感染者且CD4+细胞计数大于每立方毫米400个的人群。欧洲-澳大利亚协作组。
N Engl J Med. 1993 Jul 29;329(5):297-303. doi: 10.1056/NEJM199307293290501.
2
Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.协和试验的初步分析。协和协调委员会。
Lancet. 1993 Apr 3;341(8849):889-90. doi: 10.1016/0140-6736(93)93096-j.
3
Surrogate markers in AIDS and cancer trials.
Stat Med. 1994;13(13-14):1423-35; discussion 1437-40. doi: 10.1002/sim.4780131318.
4
5
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).对有艾滋病进展高风险的无症状HIV感染受试者每日两次服用齐多夫定：一项随机、双盲、安慰剂对照研究。欧洲-澳大利亚协作组（研究017）
AIDS. 1994 Mar;8(3):313-21. doi: 10.1097/00002030-199403000-00004.
6
Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.
Br J Haematol. 1994 Jan;86(1):174-9. doi: 10.1111/j.1365-2141.1994.tb03270.x.
7
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.无症状人类免疫缺陷病毒感染中齐多夫定治疗相关生活质量的评估。艾滋病临床试验组。
N Engl J Med. 1994 Mar 17;330(11):738-43. doi: 10.1056/NEJM199403173301102.
8
A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.齐多夫定治疗后，对人类免疫缺陷病毒感染患者使用去羟肌苷或扎西他滨的对比试验。艾滋病临床研究特里·贝恩社区项目。
N Engl J Med. 1994 Mar 10;330(10):657-62. doi: 10.1056/NEJM199403103301001.
9
Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).艾滋病临床试验临床终点选择的考量。特里·贝恩艾滋病临床研究社区项目（CPCRA）。
Stat Med. 1994;13(19-20):2107-25. doi: 10.1002/sim.4780131919.
10
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.体内HIV群体动力学：对基因变异、发病机制及治疗的影响
Science. 1995 Jan 27;267(5197):483-9. doi: 10.1126/science.7824947.
Zotero 插件